Global Pigmentation Disorders Treatment Market 2018-2026: Supportive Regulatory Environment Will Contribute Towards Market Growth
DUBLIN, Sept. 18, 2018 /PRNewswire/ --
The "Global Pigmentation Disorders Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global pigmentation disorders treatment market was valued at US$ 5311.5 Mn in 2017, and is expected to reach US$ 9649.9 Mn by 2026, expanding at a CAGR of 6.9% from 2018 to 2026.
Microdermabrasion is gaining prominence due to its growing popularity over the counter product (OTC) for the treatment of skin defects such as dark spots and wrinkles.
In the present scenario, melasma is dominating the disease type segment due to its high incidence rate in the Caucasian population, which comprises 55 to 60% of the world population. Hormonal changes, pregnancy and birth control pills are responsible for the occurrence of melasma in 90% women throughout the globe. Vitiligo will be highlighting growth at a rapid pace due to its high prevalence in Negroid and Mongoloid population. Technological advancement in photo and laser therapy has been able to treat vitiligo up to a certain extent.
North America is currently dominating the global market on account of the rising incidence of melasma and post inflammatory hyperpigmentation. Presence of major players engaged in the formulation of topical creams to treat facial hyperpigmentation caused from acne, pox and accidents drive the pigmentation disorders treatment market in North America. Asia Pacific is going to project a remarkable market growth during the forecast period due to key factors such as developing healthcare infrastructure, rise in per capita income and competitive environment created due to proliferation of local players.
Key Highlights
- Rising incidence of albinism and vitiligo in the negroid and aboriginal population
- Availability of numerous combinations of topical creams to treat face hyperpigmentation due to acne, pox, accidents etc., in the Caucasian population
- Supportive regulatory environment will contribute towards the growth of pigmentation disorders market
Key Topics Covered
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Pigmentation Disorders Treatment Market Portraiture
2.2. Global Pigmentation Disorders Treatment Market, by Treatment Type, 2017 (US$ Mn)
2.3. Global Pigmentation Disorders Treatment Market, by Disease Type, 2017 (US$ Mn)
2.4. Global Pigmentation Disorders Treatment Market, by Geography, 2017 (US$ Mn)
Chapter 3. Pigmentation Disorders Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pigmentation Disorders Treatment Market, by Key Players, 2017
Chapter 4. Global Pigmentation Disorders Treatment Market, by Treatment Type
4.1. Overview
4.2. Topical Drugs
4.3. Chemical Peels
4.4. Microdermabrasion
4.5. Phototherapy
4.6. Laser Therapy
Chapter 5. Global Pigmentation Disorders Treatment Market, by Disease Type
5.1. Overview
5.2. Melasma
5.3. Albinism
5.4. Vitiligo
5.5. Post-Inflammatory Hyperpigmentation
5.6. Others (Solar Lentigines, Acne Vulgaris, etc.)
Chapter 6. Global Pigmentation Disorders Treatment Market, by Geography
6.1. Overview
6.2. North America Pigmentation Disorders Treatment Market Analysis, 2016-2026
6.3. Europe Pigmentation Disorders Treatment Market Analysis, 2016-2026
6.4. Asia Pacific Pigmentation Disorders Treatment Market Analysis, 2016-2026
6.5. Latin America Pigmentation Disorders Treatment Market Analysis, 2016-2026
6.6. Middle East & Africa Pigmentation Disorders Treatment Market Analysis, 2016-2026
Chapter 7. Company Profiles
7.1. Allergan Plc
7.2. Bayer AG
7.3. Galderma S.A.
7.4. EpiPharm AG
7.5. Pierre Fabre Laboratories
7.6. La Roche-Posay Laboratoire Pharmaceutique
7.7. Obagi Cosmeceuticals LLC
7.8. RXi Pharmaceuticals Corporation
7.9. SkinCeuticals, Inc.
7.10. Vivier Pharma, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/8xmdpt/global?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article